Company
Evommune, Inc. (EVMN)
Standardized SEC financial data for Evommune, Inc. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0002044725 · NYSE · Pharmaceutical Preparations.
Operating margin
-623.6%
Net margin
-529.8%
Revenue growth (YoY)
85.7%
Return on equity
-33.5%
Free cash flow
-$76.7M
Current ratio
8.57×
EPS (diluted)
$-11.22
Ratios for fiscal year 2025, standardized from SEC filings.
Income statement
| USD | FY2024 | FY2025 |
|---|---|---|
| Revenue | $7.0M | $13.0M |
| R&D expense | $64.2M | $74.0M |
| SG&A expense | $12.8M | $20.0M |
| Operating income | -$70.0M |
Balance sheet
| USD | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $29.2M | $16.5M | $45.5M |
| Total current assets | — | $74.0M | $153.5M |
| Property, plant & equipment | — |
Cash flow
| USD | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | -$58.2M | -$76.4M |
| Capital expenditures | $88K | $235K |
| Free cash flow | -$58.3M | -$76.7M |
| Investing cash flow | -$4.0M |
Get EVMN data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/EVMN/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/EVMN/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"